Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07550517 · ClinicalTrials.gov registry record · Phase 2
PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Not yet
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT07550517 is a Phase 2 study that has not yet begun recruiting, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 60 participants.
The verdict
NCT07550517, a Phase 2 study, has not yet begun recruiting, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This research is being done to find out if the study drug, 177Lu-PSMA-617, given before and during standard of care External Beam Radiation Therapy (EBRT) treatment, with a shorter course of Androgen Deprivation Therapy (ADT) (6 months) is (1) safe and effective compared to standard of care alone, and (2) can reduce the side effects caused by long-term (24 months) ADT in men with high risk localized prostate cancer.
Interventions
- DRUG EBRT + 6 mo ADT + 177Lu-PSMA-617
- RADIATION EBRT + 24 mo ADT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-07 |
| Est. Completion | 2033-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07550517
The ClinicalTrials.gov registry entry for NCT07550517 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which EBRT + 6 mo ADT + 177Lu-PSMA-617 is the first listed.
NCT07550517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07550517 about?
NCT07550517 is a clinical study titled "PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT". This research is being done to find out if the study drug, 177Lu-PSMA-617, given before and during standard of care External Beam Radiation Therapy (EBRT) treatment, with a shorter course of Androgen Deprivation Therapy (ADT) (6 months) is (1) safe and effective compared to standard of care alone, a...
What is the current status of trial NCT07550517?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2026-07. Estimated completion is 2033-07.
What interventions are being tested in trial NCT07550517?
The interventions under investigation include: EBRT + 6 mo ADT + 177Lu-PSMA-617 (DRUG), EBRT + 24 mo ADT (RADIATION).
Who is sponsoring clinical trial NCT07550517?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.